Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Pfizer Inc. closed 18.10% below its 52-week high of $31.54, which the company reached on July 30th.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report). The company’s ...

Pfizer in a statement said it was pleased Do No Harm had decided to voluntarily dismiss the case, which the company said had no merit. The New York-based company changed the program's criteria in ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares opened ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

Q4 2024 Management View CEO Albert Bourla highlighted Pfizer's strong execution in 2024, emphasizing the successful integration of Seagen, which has positioned Pfizer as a leading oncology company. He ...

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations. On the cost side, Pfizer achieved $4 billion in savings ...